ESC 2022 preview – can Farxiga Deliver?
Astrazeneca’s SGLT2 inhibitor has hit in HFpEF, but can it outdo Jardiance?
ESC 2021 – Jardiance blows Entresto out of the water
A 21% reduction in the risk of cardiovascular death or hospitalisation paves the way for Jardiance's approval in heart failure with preserved ejection fraction.
Roxadustat shows the latest regulatory fault line split
Fibrogen’s controversial anaemia pill becomes the latest example of markedly different regulatory stances taken in Europe and the US.
ACC 2021 – Esbriet could Pirouette into heart failure
The IPF drug shows surprising promise in heart failure with preserved ejection fraction.
The biotech resurrection continues
Positive surprises with Lexicon’s Zynquista and DBV’s Viaskin Peanut show that you can never entirely write biotech off.
AHA 2020 – sotagliflozin wins come too late for Lexicon
But the Soloist trial suggests a benefit in heart failure with preserved ejection fraction, which might be good news for Lexicon’s SGLT2 rivals.
